Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced the launch of the CFX Opus Deepwell Dx Real-Time PCR System, a real-time PCR system listed with the U.S. Food and Drug Administration (FDA) for in vitro diagnostic (IVD) testing, and developed in accordance with the European Union’s regulations for in vitro diagnostic medical devices (EU 2017/746). Bio-Rad will continue to seek regulatory approvals for additional global markets in the coming months.
The CFX Opus Deepwell Dx Real-Time PCR System is the latest addition to the Bio-Rad portfolio of real-time PCR instruments. The system offers accurate and precise quantification with flexibility for reactions up to 125 µl in a 96-well format for quantitative PCR (qPCR) diagnostic assays. The CFX Opus Dx Real-Time PCR System is also available in a 96- and 384-well reaction block format. All systems in the CFX Opus Dx Real-Time PCR family are open platforms that can multiplex up to five targets to enable efficient IVD assay development and diagnostic testing. CFX Opus Dx Real-Time PCR Systems offer easy-to-use desktop management and analysis software with integrated security features for electronic signature, audit, and user control.
“With the ongoing increase in demand for efficient and flexible IVD real-time PCR systems, we are pleased to announce the addition of the CFX Opus Deepwell Dx Real-Time PCR System to the CFX Opus family,” said Steven Blakely, Senior Director for the Gene Expression Business, Bio-Rad. “The CFX Opus Deepwell Dx Real-Time PCR System continues in the tradition of robust and secure platforms that leverage the long-standing Bio-Rad expertise in genomic tools to serve both research and clinical diagnostic markets,” he added.
Please visit bio-rad.com/cfxopus-dx to learn more about the Bio-Rad CFX Opus Dx Detection Systems for in vitro diagnostics.
BIO-RAD is a trademark of Bio-Rad Laboratories, Inc.